Search clinical trials for: Biktarvy

Total 72 results

Tulika Singh, MD
Gilead Sciences

Recruiting

Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age

HIV-1-infection

United States
Gilead Sciences

Recruiting

Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)

HIV-1-infection

United States, France, Canada
Judit Pich Martínez
Gilead Sciences

Completed

A Test and Treat Strategy in New HIV Diagnosis. (Test&Treat)

HIV-1-infection

Spain
Professor Saye Khoo MD, FRCP

Unknown

How Does Antiretroviral Therapy Affect Coronary Atherosclerosis: A Serial CT Study (HART CT)

Coronary Artery Disease | Hiv
NEAT ID Foundation
Gilead Sciences; Janssen Pharmaceuticals

Active, not recruiting

The Late Presenter Treatment Optimisation Study (LAPTOP)

HIV/AIDS

Spain, Ireland, France, United Kingdom, Germany, Italy, Belgium
Southampton Healthcare, Inc.

Terminated

Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy

HIV-1-infection

United States
Institut de Médecine et d'Epidémiologie Appliquée...

Unknown

Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST (FAST)

HIV Seropositivity

France
Chelsea and Westminster NHS Foundation Trust
Gilead Sciences; Imperial College London

Completed

Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat' (BIC-T&T)

Human Immunodeficiency Virus

United Kingdom
Institut de Médecine et d'Epidémiologie Appliquée...
LAMBERT ASSOUMOU/ UNITE 1136 INSERM; Sebastien GALLIEN/Henri Mondor University... and other collaborators

Active, not recruiting

Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF (KINETIK)

HIV-infected Patient Kidney Transplant Recipient

France
Emory University

Completed

Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM

HIV | ART

United States
University Hospital, Caen

Completed

Bioequivalence of Solid/Crushed/Dissolved Forms of Biktarvy® (SOLUBIC)

Healthy Volunteers

France
Gilead Sciences

Active, not recruiting

Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (BIC-STaR)

HIV-1-infection

Canada
Gilead Sciences

Completed

Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) (BIC-STaR)

HIV-1-infection

Israel
Gilead Sciences

Completed

Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

HIV-1 Infection

Spain, United Kingdom, France, Italy, Belgium
Dr. Bertrand Lebouche

Recruiting

Antiretroviral Speed Access Program (ASAP)

HIV Infection

Canada
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (BRAAVE 2020)

HIV-1 Infection

United States
Gilead Sciences
Merck Sharp & Dohme LLC

Active, not recruiting

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

HIV-1 Infection

United States
Fundacion Clinic per a la Recerca Biomédica

Active, not recruiting

Safety, Tolerability, and Efficacy of a Dose Reduction Strategy Based on Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-infected Adults (BETAF-RED)

HIV Infections

Spain
University of Nairobi
Gilead Sciences

Active, not recruiting

BFTAF Elderly Switch Study (BFTAF)

HIV-1-infection

Kenya
Gilead Sciences

Completed

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

HIV-1 Infection

United States
Radboud University Medical Center
Merck Sharp & Dohme LLC; ZonMw: The Netherlands Organisation for Health Research...

Recruiting

Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteers (PANNA-B PK)

Hiv

Netherlands
Fundacion SEIMC-GESIDA

Active, not recruiting

Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities (MIND)

HIV Infections

Spain
Emory University
Centers for Disease Control and Prevention

Completed

Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens

Sexually Transmitted Diseases

United States
National Institute of Allergy and Infectious Diseases...

Not yet recruiting

A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

Acute HIV Infection

United States, Brazil, Peru
State University of New York at Buffalo
Gilead Sciences

Active, not recruiting

Bictegravir in the Elderly Living With HIV (BICEP)

HIV-1-infection

United States
Atea Pharmaceuticals, Inc.

Not yet recruiting

Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir

Healthy Volunteer Study

Canada
Gilead Sciences

Recruiting

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

HIV-1 Infection

United States, Thailand, Uganda, South Africa
Gilead Sciences

Recruiting

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy (ARTISTRY-2)

HIV-1-infection

United States
Virginia Commonwealth University
Indivior, PLC.

Withdrawn

Virginia Opioid Treatment-Emergency Department (VOT-ED)

Opioid Use Disorder
Gilead Sciences

Recruiting

Study of Novel Antiretrovirals in Participants With HIV-1

HIV-1-infection

United States, Thailand, Dominican Republic
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

HIV-1 Infection

United States, France, Austria, Germany
Weill Medical College of Cornell University
Gilead Sciences

Active, not recruiting

Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant

HIV Infections | Renal Transplant Rejection

United States
Institut de Médecine et d'Epidémiologie Appliquée...
Pierre and Marie Curie University

Recruiting

Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication (BICOLDER)

HIV Infections

France
University of Miami

Completed

Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program

HIV Infections | Drug Use | Harm Reduction

United States
Chelsea and Westminster NHS Foundation Trust
Gilead Sciences; Imperial College London

Terminated

Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH

Human Immunodeficiency Virus

United Kingdom
Anna Cruceta

Recruiting

Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection (BIC-PHI)

HIV Primary Infection

Spain
Chelsea and Westminster NHS Foundation Trust

Recruiting

The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers

HIV-1-infection

United Kingdom
Valley AIDS Council
Gilead Sciences

Not yet recruiting

Advanced HIV: Outcomes for Rapid ART (AHORA)

HIV-1-infection
University of Nebraska
Gilead Sciences

Completed

Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE (BASE)

HIV-1-infection

United States
University of Southern California

Active, not recruiting

Empiric Treatment for Acute HIV in the ED (EMTreatED)

Acute HIV Infection

United States
National Taiwan University Hospital
Mackay Memorial Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital and other collaborators

Unknown

Same-day Antiretroviral Therapy With BIC/F/TAF

HIV Infections

Taiwan
Prism Health North Texas
Merck Sharp & Dohme LLC

Withdrawn

Doravirine and Weight Gain in Antiretroviral Naive (DAWN)

Obesity | Metabolic Syndrome | Body Weight Changes | Human Immunodeficiency Virus | Fasting | Minority Health | ART | BMD

United States
Quest Clinical Research
Gilead Sciences

Completed

Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine

HIV-1-infection

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

HIV-1 Infection

United States, France, Switzerland
Midland Research Group, Inc.
Gilead Sciences

Completed

Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1

Human Immunodeficiency Virus

United States
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-56136379 in Healthy Participants

Healthy
Brigham and Women's Hospital
Boston Medical Center; Tufts Medical Center

Completed

Effects of Biktarvy on CFR in Stable HIV Patients (BETTER)

HIV

United States
Fundacion SEIMC-GESIDA

Active, not recruiting

Simplified Model of Linkage and Retention to Care, Using a Mobile Unit and a Same-day Test and Treat Approach Among Excluded Population. (SIMPLIFIED) (SIMPLIFIED)

HIV Infections

Spain
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With Other Antiretroviral Agents in People Living With HIV (CALIBRATE)

HIV-1-infection

United States, Puerto Rico, Dominican Republic
MU-JHU CARE

Recruiting

BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study (BONE:STAR)

Bone Loss

Uganda

3

Subscribe